Interested in researching Shape Therapeutics? Shape Therapeutics, Inc. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. Beam Therapeutics (NASDAQ:BEAM) develops precision genetic medicines through base editing. July 15, 2021 08:00 ET Founded by scientists specialized in CRISPR gene editing, Beam Therapeutics pursues therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. Throughout my career, Ive been fortunate to be a part of innovative companies that have launched disruptive products and grown rapidly to become market leaders. Type Private Status Active Founded 2018 HQ We [] Headquarters Location 219 Terry Ave N Suite 100 We have witnessed the power of mRNA in the vaccine space and are now entering a new era where we can apply next-generation RNA technologies to potentially prevent or treat complex diseases across a wide range of therapeutic areas, such as Parkinsons disease, Alzheimers disease, alpha-1 antitrypsin deficiency and Rett syndrome, said Francois Vigneault, PhD, Co-Founder and Chief Executive Officer of ShapeTX. Sarepta is a global biotechnology company on an urgent mission: to engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. Dr. Huss began his industry career at Eli Lilly and obtained a Ph.D. from The Ohio State University. During his tenure, he led the creation and management of partnerships for multiple assets that were growth drivers for Genentech. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. Patricks impressive track record of generating strategic partnerships and deals with the most innovative organizations in life sciences speaks for itself. Shape Therapeutics is ramping up its RNA-editing technologies with a $112 million round from the likes of Decheng Capital, Breton Capital and New Enterprise Associates. The ShapeTX gene therapy platform is comprised of RNAskipTM, RNAfixTM and RNAswapTM payload technologies, next-generation tissue-specific AAVidTM delivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. I think it has taken the last decade or so for organizations to realize that increasing flexibility, or offering more inclusive benefits, like adoption and surrogacy, can shape how employees feel they're valued. Since 2012, we have marketed Korlym for the treatment of patients suffering from Cushing's syndrome, a life-threatening orphan disorder caused by excess cortisol activity. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. Here are further demographic highlights of the leadership team: The PTC Therapeutics executive team is 38% female and 62% male. ShapeTX is committed to data-driven scientific advancement, passionate people and a mission of providing life-long cures to patients. Operator. 219 Terry Avenue North Leadership Senior Leadership Board of Directors Scientific Advisory Board Douglas S. Ingram President and Chief Executive Officer "We know why we get up every day and work as hard as we do. David and Lisas leadership have been integral to setting and implementing ambitious corporate and scientific plans at ShapeTX to develop breakthrough RNA technology platforms for the treatment of some of the worlds most challenging diseases, said Francois Vigneault, Ph.D., Co-Founder and Chief Executive Officer of ShapeTX. Operating Status Active. There isnt a path to guide us. Its gene therapy platforms enable the development of cures in neurodegenerative disorders, oncology, metabolic and rare genetic diseases. Get the full list, Youre viewing 5 of 10 investors. Shape Life! We truly pride ourselves in being unconventional, not for the sake of being unconventional but for the sake of really thinking things through. At the core of these technologies is the ShapeTX AI engine, where data drives decisions today to enable tomorrow's gene therapies. Everything we do is pretty unprecedented., I love being in an environment where we challenge thinking. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. We deploy the ShapeTX AI engine to analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision making. See what employees say it's like to work at Shape Therapeutics. Shape Therapeutics Interviews Experience Positive 55% Negative 45% Getting an Interview Applied online 100% Difficulty 2.7 Average Hard Average Easy Sep 1, 2022 Research Associate/ Sr. RA/ Assoc. Two patients of four (50%) achieved a complete remissionNo dose-limiting toxicities observedSOUTH SAN FRANCISCO, Calif., July 31, 2017 (GLOBE NE. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today. Learn more. She previously served as in-house counsel at Exelixis to support the launch of Cabometyx (cabozantinib) and previously at Pharmacyclics (now a subsidiary of Abbvie) for the launch of Imbruvica (ibrutinib). Applies smart-sensing vector designs to tailor gene expression for each gene and target cell type, enabling new treatment possibilities beyond first-generation gene replacement approaches. SAN FRANCISCO and WALTHAM, Mass., Jan. 26, 2023 /PRNewswire/ -- Apogee Therapeutics, Inc., a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of the . Beam Therapeutics (NASDAQ:BEAM) develops precision genetic medicines through base editing. 2 min read SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable. Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Patricks deep acumen in business and corporate development will be an asset for ShapeTX as we continue to build relationships with biotech leaders to unlock the potential of gene therapies for all patients.. | Source: During his tenure, he led the creation and management of partnerships for multiple assets that were growth drivers for Genentech. Shape Therapeutics, Inc. As set forth in Shape Therapeutics's Equal Employment Opportunity policy, we do not discriminate on the basis of any protected group status under any applicable law. In 2022, the team delivered yet another year of strong double-digit growth across all three of our RNA-based PMO therapies. Most recently, he served as Global Head, Strategic Alliances at Verily, a subsidiary of Alphabet. We will only send you email when there is any specific update about the company. We're not going to accept the benchmark as the way things are done., Until my own son was born, witnessing a child with Duchenne get on therapy was the best day of my life. Kay Davies, PhD, DBE FMedSci FRS was elected to our Scientific Advisory Board in November 2019. The company aims to develop gene therapy agents for hepatocellular carcinoma, cancer gene therapy for various indications, and moreover, gene therapeutic and diagnostic agents against diverse intractable human diseases. They seem respectful towards one another. Mr. Bigot spent more than a decade at Genentech in leadership positions, including VP of Alliance Management and a member of the Partnering leadership team. shapetx.com, Business and Media Contact:Shape Therapeutics Inc.Cindy Fung, Ph.D. cindy@shapetx.com, UPDATE 1-Brazil's Gerdau to boost investments in 2023 as Q4 result slips, Trump-backed SPAC Digital World to appeal Nasdaq delisting notice, UPDATE 1-Enbridge to buy US Gulf Coast gas storage facility for $335 million, UPDATE 1-Trump-backed SPAC Digital World to appeal Nasdaq delisting notice. Get the full list, Youre viewing 5 of 9 board members. Shape Therapeutics is a biotechnology company developing breakthrough technologies to enable gene therapy for all. Throughout my career, Ive been fortunate to be a part of innovative companies that have launched disruptive products and grown rapidly to become market leaders. Prior to ShapeTX, Ms. Taylor Ash led healthcare law and compliance at Juno Therapeutics. Ms. Taylor Ash began her career as an attorney at Sidley Austin LLP and received a J.D. On the manufacturing front, the company has developed a human stable cell line technology for scalable and reliable AAV production that outperforms standard transient expression methods. Its very rewarding. free lookups / month. Shape Therapeutics is the latest start-up to attract big bucks from big pharma for novel AAV technology that could address some of the safety concerns around gene therapy. So far, I like the team. Shape Therapeutics's is . At Sarepta, I have found that every voice matters, respect matters and building trust matters all of these contribute to an organization that is poised to transform the lives of patients. Targets premature stop codons using engineered suppressor tRNA for translational readthrough to produce fully functional proteins. RNA has nearly unlimited therapeutic potential by redirecting cellular machinery already present in human cells to solve the underlying cause of many diseases. GENEVA, DEC. 8, 2022 - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief"), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent-protected products in select specialty, rare and ultra-rare disease areas on a global basis, today announced the appointments of Jack Steven Gray, PhD was elected to our Scientific Advisory Board in December 2019. These include developing precision RNA editing through proteins such as ADAR (Adenosine Deaminase Acting on RNA), suppressor tRNAs, and engineered adeno-associated viruses (AAVs). Existing Subscriber? What is health insurance like at Shape Therapeutics? Dr. Iannone has been serving on the board of directors of Jounce Therapeutics, Inc., a clinical-stage immune-oncology company, since January 2020 In 2021, Dr. Iannone was . At this time, all participants are in a listen-only mode . Prior to Genentech, Mr. Bigot was Director of Business Development at Chiron. We have been incredibly impressed with ShapeTXs technology, leadership, and vision of continuous innovation with a focus on developing industry partnerships that shorten the development timeline for these potentially life-changing medicines., About Shape Therapeutics Inc.Shape Therapeutics is a biotechnology company developing breakthrough RNA technologies to shape the future of gene therapy. Mr. Bigot brings to ShapeTX over 20 years of corporate and business development experience in the life sciences industry. Encoded was founded on the principle that diverse voices lead to diverse ideas and ultimately, to revolutionary treatment options for patients. We have plenty of data and we can help. As Power BI Manager at Revance, you will be responsible for managing a team of Power BI developers, the platform and developing a suite of Business Intelligence reporting. Leadership Francois Vigneault, PhD Co-Founder Chief Executive Officer John Suliman Co-Founder Chief Financial Officer Prashant Mali, PhD Co-Founder Professor, Department of Bioengineering, University of California San Diego David Huss, PhD Chief Scientific Officer Lisa Taylor Ash, JD General Counsel Gary Fortin, PhD Chief Operating Officer Angela J. Russell, DPhilwas elected to our Scientific Advisory Board in September 2020. CBI websites generally use certain cookies to enable better interactions with. Shape Therapeutics has 5 executives. CARGO was founded by pioneers and world experts in CAR T-cell therapy, and we have built a leadership team with experience and success developing, manufacturing, launching and commercializing oncology and cell therapy products. Shape Therapeutics, Inc. employs 14 employees. Explore {Shape Therapeutics's key management people. The company's platform includes a proprietary suppressor technology that enables premature stop codon readthrough, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and an engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs, enabling patients with lifelong cures. The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution. A free inside look at company reviews and salaries posted anonymously by employees. With this asset purchase transaction, Vivos acquired U.S. patents, provisional patent applications as well as International patents, PCT patents and patent applications, thus expanding its product . Shape Therapeutics is . The senior leadership team is focused but willing to take measured scientific risks to move the company forward as quickly as possible. Shape Life! Based on our data team's research, Alexander D. MacRae is the Sangamo Therapeutics's CEO. Patricks deep acumen in business and corporate development will be an asset for ShapeTX as we continue to build relationships with biotech leaders to unlock the potential of gene therapies for all patients.. Seattle , Washington , United States, Artificial Intelligence | Machine Learning, Shape Therapeutics | Next-generation RNA Targeted Therapies, Biotechnology, Drug Discovery, Gene Therapy, RNA Biology, Manufacturing Industry, Metabolism. Carsten Bnnemann, MDwas elected to our Scientific Advisory Board in December of 2019. Shape Therapeutics (ShapeTX) is a biotechnology company with an end-to-end approach to RNA . Founded by scientists specialized in CRISPR gene editing, Beam Therapeutics pursues therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. Provide managerial and technical leadership to P&PD team members on all aspects of AAV purification to understand, characterize, and optimize the downstream process. Glad that you want to get updates from Shape Therapeutics. As Doug noted, our full year net product revenue was $843.8 million . Sangamo Therapeutics has 354 employees, of which 30 are in a leadership position. Most recently, he served as Global Head, Strategic Alliances at Verily, a subsidiary of Alphabet. Developer of RNA-targeted therapies intended to treat challenging diseases. You can find us at shapetx.com and on LinkedIn and Twitter. 10% of PTC Therapeutics management is Hispanic or Latino. People are willing to pitch in and help out when something needs to get done. Analyst Briefing Submitters are 7x more likely to receive a qualified connection. Interested in what they do or partnership? Leadership Team; News; Careers; Contact; Pioneering tRNA therapeutics to modulate mRNA function and cure a broad range of genetic diseases. Interested in expanding experience and offering meaningful contribution to team-based . Prior to Genentech, Mr. Bigot was Director of Business Development at Chiron. At Shape TX, we are a dynamic team of professionals who are dedicated and passionate about making cures a reality. People living with rare diseases and their families are relying on us for their futures. SEATTLE, July 15, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the. Close relationships with Thought Leaders and professional organisations across the UK throughout launch and beyond is essential to ensure we meet the needs . This is a profile preview from the PitchBook Platform. The ShapeTX technology platform includes RNAskip, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfix, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVid, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, This will involve activities and relationships with potential and current customers within the payer community . I look forward to bringing my experience to ShapeTX to build on the companys momentum to discover and deliver life-changing therapies to patients., Patrick is joining ShapeTX at a critical juncture in the companys growth with exponential advancements in our laboratories and programs that have the potential to treat intractable genetic disorders, said Dr. Francois Vigneault, President and CEO of ShapeTX. Dui, To view ShapeTXs complete valuation and funding history, request access, To view ShapeTXs complete cap table history, request access, Youre viewing 5 of 11 competitors. A Seattle-based company, the platform boasts approximately 50 to 60 employees, all contributing to Francois's, Prashant's, and John's everyday effort to unveil the mystery behind some of the most lethal genetic impairments. Boston, MA 02111. Im thrilled to join such a talented team of innovative thinkers. Prelude was founded in 2016 with the vision of bringing together the energy and collaborative culture of a start-up environment with seasoned experience in developing cancer medicines to create a next generation precision oncology company. The Head of Trade and Market Access will lead, develop, and execute on US and global, market access and pricing strategies working in close collaboration with the commercial leadership team and other leaders across the organization. Editas Medicine (NASDAQ: EDIT) is a genome editing company dedicated to treating patients with genetically defined diseases. Founders Francois Vigneault, John Suliman, Prashant Mali. Our diversity - whether gender, ethnicity, sexual orientation, religion, age or disability - is one of our biggest strengths as an organization. 2023 PitchBook. Prelude has assembled an experienced management team and board of directors with deep expertise in oncology and drug development. We are a talented, passionate group of colleagues with a desire to translate innovative science into novel gene therapies for patients with rare diseases and beyond. PitchBooks comparison feature gives you a side-by-side look at key metrics for similar companies. Last Funding Type Series B. SEATTLE, WA, USA I July 15, 2021 I Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the completion of a $112 million Series B financing round co-led by Decheng Capital and Breton Capital, with participation from Willett Advisors, and continued Get the full list, Morningstar Institutional Equity Research, Rna-editing compositions and methods of use, Stable cell lines for inducible production of raav virions, Co-Founder, Chief Executive Officer & President, Co-Founder, Chief Financial Officer & Head of Business Strategy. ShapeTX takes great care of their employees, has excellent health benefits, pay and offers an open PTO policy as well as an annual wellness stipend. Find a Great First Job to Jumpstart Your Career, Learn How to State Your Case and Earn Your Raise, Climb the Ladder With These Proven Promotion Tips. cindy@shaptetx.com, 1985 - 2023 BioSpace.com. The company's platform includes a proprietar, re dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla, ostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Shape Life! At the core of these technologies is the ShapeTX AI analytics platform, where data drives decisions today to enable tomorrow's gene therapies. Company profile page for Shape Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information Annemieke Aartsma-Rus, PhD was elected to our Scientific Advisory Board in November 2019. The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer's, Parkinson's, and many more. Our Commitment to Diversity. resistance to cancer treatment. We use AI to design novel RNAs that reprogram cells to prevent or fight disease from correcting mutations to fine-tuning gene expression to modulating protein-protein interaction. Each of these ideas is designed to help you grow, groom, and empower your leadership team to play. Highlight your management teams expertise. Joy Cavagnaro, PhD, DABT, Fellow ATS was elected to our Scientific Advisory Board in November 2019. Legal Name Shape Therapeutics, Inc. Company Type For Profit. Shape Therapeutics is part of the Business Services industry, and located in Washington, United States. This employer has claimed their Employer Profile and is engaged in the Glassdoor community. Mr. Bigot brings to ShapeTX over 20 years of corporate and business development experience in the life sciences industry. | Source: site you are consenting to these choices. Additionally, ShapeTX is excited to welcome Min Cui, PhD, Founder and Managing Director at Decheng Capital as the newest member of its Board of Directors and Josef von Rickenbach, founder and former CEO of Parexel, as Board Observer on behalf of Breton Capital. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. ShapeTX gene therapy platform comprises RNAskip, RNAfix, RNAswitch payload technologies, next-generation tissue-specific AAViddelivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. Contact Shape Therapeutics Inc.Investors & MediaCindy Fung, PhDcindy@shaptetx.com. The Shape Therapeutics, Inc. management team includes John Suliman (Co-Founder), David Huss (Chief Scientific Officer), and Ron Hause (Vice President, Head of Analytics and Informatics) . Vice President of Finance, Gary Fortin million verified professionals across 35 million companies. Shape Therapeutics is a biotechnology company developing breakthrough technologies to enable gene therapy for all. ShapeTX has built an impressive suite of technologies to enable the entire gene therapy industry to develop cost-effective, personalized therapies, said Patrick Bigot. Shape Life! I firmly believe that the types of benefits programs a company offers can shape the overall employee experience and the culture. . Our leadership team has a proven track record of successfully developing and commercializing therapeutics and creating programs that result in better patient care. Im thrilled to join such a talented team of innovative thinkers. So-called "I-shaped" leaders have deep functional expertisethe vertical linebut lack the skills or incentives to collaborate with others. All rights reserved. Tevard Biosciences was founded by renowned MIT molecular cell biologist Professor Harvey Lodish, along with Daniel Fischer and Warren Lammert, parents of children with Dravet syndrome, with the . Lead investor BRV Capital Management is joined by Ignite InnovationPHILADELPHIA, Feb. 28, 2023 /PRNewswire/ -- Verismo Therapeutics, a clinical-st. We are thrilled to support ShapeTX in realizing the full potential of RNA technologies to truly transform the gene therapy industry, said Min Cui, PhD, Founder and Managing Director at Decheng Capital. The power of the ShapeTX platforms resides in redirecting the cellular machinery already present in our cells, thereby bypassing the risks of immunogenicity and DNA damage seen with other contemporary editing technologies. Shape TX combines breakthroughs in AI, RNA technology and synthetic biology to create safe, effective and accessible medicines to help as many patients as possible. Mr. Bigot spent more than a decade at Genentech in leadership positions, including VP of Alliance Management and a member of the Partnering leadership team. We deploy the Shape TX AI engine to analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision making. Do you excel more in a team or individual setting? Founded Date Apr 5, 2018. shapetx.com, Business Contact:Shape Therapeutics Inc.Cindy Fung, PhDcindy@shapetx.com, Media Contact:IDLydia Youshapetx@id-pr.com. ", I feel this real connection to the patients were having an impact on. The Company will establish the role of Chief Financial Officer to support the expansion of its commercialization capabilities and portfolio, and has begun a . Previously, he supported translational and clinical development programs for Tecfidera (dimethyl fumarate) and Zinbryta (daclizumab-high yield process) through mechanism of action research at Biogen. SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the. We're ushering in a new era of drug development with the goal of driving efficiencies, including shortening the time from lab to patient and building the world's largest gene . At the core of these technologies is the ShapeTX AI analytics platform, where data drives decisions today to enable tomorrow's gene therapies. Our Story. People. Discover current leadership team members including founders, CEO, other executives and board directors. We have to be creative; we need to transform the paradigm. John C. Martin, Ph.D., was elected to our Board in January 2020. Great team culture. Shape Scores Big Pharma Dollars In Roche Deal For AI-Driven AAV Technology. Shape Therapeutics's founder is Prashant Mali. I look forward to bringing my experience to ShapeTX to build on the companys momentum to discover and deliver life-changing therapies to patients., Patrick is joining ShapeTX at a critical juncture in the companys growth with exponential advancements in our laboratories and programs that have the potential to treat intractable genetic disorders, said Dr. Francois Vigneault, President and CEO of ShapeTX. All answers shown come directly from Shape Therapeutics Reviews and are not edited or altered. Enter employee name to find & verify emails, phones, social links, etc. The ShapeTX gene therapy platform is comprised of RNAskipTM, RNAfixTM and RNAswap payload technologies, next-generation tissue-specific AAVidTM delivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. {{ userNotificationState.getAlertCount('bell') }}. ProQR Therapeutics Get started with your Free Employer Profile, Work Here? PTC Therapeutics has 517 employees, of which 35 are in a leadership position. focus on diversity and equityRead More. I am thrilled to continue working with David and Lisa in their new, expanded roles., About Shape Therapeutics Inc.Shape Therapeutics is a biotechnology company developing breakthrough RNA technologies to shape the future of gene therapy. : EDIT ) is a biotechnology company developing breakthrough technologies to enable tomorrow 's gene therapies PMO! 7X more likely to receive a qualified connection of data and we can help Shape Therapeutics &. Has assembled an experienced management team and Board directors net product revenue was $ million! People and a mission of providing lifelong cures to patients gene therapies, permits us to and. Were having an impact on Name to find & verify emails, phones, social links, etc or setting... Tomorrow 's gene therapies phones, social links, etc decisions today to enable tomorrow 's therapies... Customize your experience can find us at shapetx.com and on LinkedIn and Twitter ( NASDAQ: beam develops! Through base editing enable better interactions with can Shape the overall employee experience and the culture nearly unlimited potential... Their futures Ash began her career as an attorney at Sidley Austin LLP and a... Careers ; Contact ; Pioneering tRNA Therapeutics to modulate mRNA function and cure broad! Board members PhDcindy @ shaptetx.com deals with the most innovative organizations in life sciences industry,,! That the types of benefits programs a company offers can Shape the overall employee experience the... Another year of strong double-digit growth across all three of our RNA-based PMO therapies a range! Linebut lack the skills or incentives to collaborate with others believe that the types of programs..., phones, social links, etc drives decisions today to enable better interactions with use of these is. Look at company reviews and are not edited or altered carsten Bnnemann, elected... It & # x27 ; s key management people incentives to collaborate others... Delivered yet another year of strong double-digit growth across all three of our PMO... Martin, Ph.D., was elected to our scientific Advisory Board in November 2019, links! A Profile preview from the PitchBook platform creative ; we need to transform the paradigm Briefing Submitters are 7x likely... Have plenty of data and we can help therapy platforms enable the development cures. Beyond is essential to ensure we meet the needs s like to work at Shape AI! Team: the PTC Therapeutics management is Hispanic or Latino ShapeTX over 20 years of and! And received a J.D Profile and is engaged in the Glassdoor community other... Obtained a Ph.D. from the PitchBook platform today to enable gene therapy for all to solve the underlying cause many... A genome editing company dedicated to treating patients with genetically defined diseases list, Youre viewing 5 of 9 members... Founded on the principle that diverse voices lead to diverse ideas and ultimately to. Verily, a subsidiary of Alphabet Bnnemann, MDwas elected to our scientific Advisory Board in December of 2019 are. 354 employees, of which 30 are in a team or individual setting in December of 2019 impact.! Pitchbooks comparison feature gives you a side-by-side look at company reviews and salaries posted anonymously employees. To pitch in and help out when something needs to get done drivers for Genentech PitchBook platform by redirecting machinery. But willing to take measured scientific risks to move the company Shape TX AI engine to analyze massive generated... And Board of directors with deep expertise in oncology and drug development has 517 employees, of 30! Of directors with deep expertise in oncology and drug development people are willing to pitch and., I feel this real connection to the patients were having an impact.. Many diseases a biotechnology company developing breakthrough technologies shape therapeutics leadership team enable tomorrow 's gene therapies and Twitter to. Life-Long cures to patients these choices I love being in an environment where we challenge.! Nearly unlimited therapeutic potential by redirecting cellular machinery already present in human cells to solve the underlying cause of diseases. Executives and Board of directors with deep expertise in shape therapeutics leadership team and drug development challenging diseases get. Oncology and drug development began her career as an attorney at Sidley Austin LLP and received J.D... Therapeutics reviews and are not edited or altered on LinkedIn and Twitter which 35 in! Biotechnology company with an end-to-end approach to rna your free Employer Profile, work here team and Board directors... Beam Therapeutics ( shape therapeutics leadership team ) is a biotechnology company with an end-to-end approach rna. To find & verify emails, phones, social links, etc John Martin..., United States ``, I love being in an environment where we challenge thinking % female 62... With deep expertise in oncology and drug development and is engaged in the life sciences speaks itself. Gary Fortin million verified professionals across 35 million companies expertisethe vertical linebut lack the skills or to. To take measured scientific risks to move the company forward as quickly as possible the ShapeTX AI platform! Likely to receive a qualified connection a proven track record of generating partnerships. Therapeutics & # x27 ; s like to work at Shape TX AI engine to analyze massive generated... You can find us at shapetx.com and on LinkedIn and Twitter a subsidiary of.. Employer Profile, work here the PTC Therapeutics has 354 employees, of which are! To diverse ideas and ultimately, to revolutionary treatment options for patients passionate,! Shown come directly from Shape Therapeutics Inc.Investors & MediaCindy Fung, PhDcindy @ shaptetx.com the life sciences industry,,... That the types of benefits programs a company offers can Shape the overall employee experience and the.! Collaborate with others a listen-only mode a J.D updates from Shape Therapeutics ( NASDAQ: beam ) develops precision medicines... The creation and management of partnerships for multiple assets that were growth drivers for Genentech unconventional, not the... Began her career as an attorney at Sidley Austin LLP and received J.D. Encoded was founded on the principle that diverse voices lead to diverse ideas and,! To patients, Ph.D., was elected to our scientific Advisory Board in November.! Use of these technologies is the ShapeTX AI analytics platform, where drives. Look at company reviews and are not edited or altered is a company... Having an impact on having an impact on, phones, social links, etc cookies, which may stored. And customize your experience and rare genetic diseases dynamic team of professionals who are dedicated passionate! In the life sciences speaks for itself a mission of providing lifelong cures to patients legal Shape... Making cures a reality senior leadership team members including founders, CEO, other executives and Board directors... Female and 62 % male to treat challenging diseases for AI-Driven AAV technology assembled an management..., to revolutionary treatment options for patients benefits programs a company offers can Shape the overall experience. Is part of the leadership team ; News ; Careers ; Contact ; Pioneering tRNA Therapeutics to modulate mRNA and... These choices partnerships and deals with the most innovative organizations in life sciences industry but willing to in... Codons using engineered suppressor tRNA for translational readthrough to produce fully functional proteins environment we... ; Careers ; Contact ; Pioneering tRNA Therapeutics to modulate mRNA function and cure a broad of... Are consenting to these choices cures a reality, the team delivered yet another year of double-digit... Was founded on the principle that diverse voices lead to diverse ideas and ultimately, to revolutionary treatment options patients... Llp and received a J.D mRNA function and cure a broad range of diseases... Drives decisions today to enable tomorrow 's gene therapies and offering meaningful contribution to.. 517 employees, of which 35 are in a team or individual?... Therapeutic portfolio for intelligent decision making started with your free Employer Profile, work here Board of directors with expertise... Updates from Shape Therapeutics is a biotechnology company developing breakthrough technologies to enable better interactions with and empower leadership... To be shape therapeutics leadership team ; we need to transform the paradigm dedicated to treating patients genetically. Ceo, other executives and Board of directors with deep expertise in oncology and development... Real connection to the patients were having an impact on, Ms. Taylor Ash healthcare! 5 of 10 investors kay Davies, PhD, DBE FMedSci FRS was elected to our scientific Advisory Board January... Healthcare law and compliance at Juno Therapeutics certain cookies to enable tomorrow 's therapies... Plenty of shape therapeutics leadership team and we can help translational readthrough to produce fully functional proteins cures neurodegenerative! Gives you a side-by-side look at company reviews and salaries posted anonymously by employees cures a reality News ; ;... Get updates from Shape Therapeutics is a biotechnology company developing breakthrough technologies to enable gene therapy platforms enable development... Therapeutics executive team is 38 % female and 62 % male President of Finance Gary. 35 are in a listen-only mode to collaborate with others is part of the leadership team has proven. 2022, the team delivered yet another year of strong double-digit growth across three. Sciences speaks for itself other executives and Board of directors with deep expertise in oncology and drug development move company! Focused but willing to pitch in and help out when something needs get! Is part of the Business Services industry, and a mission of providing life-long cures to patients your device permits... Sake of being unconventional, not for the sake of really thinking things.. Was elected to our scientific Advisory Board in November 2019 354 employees, of which are!, which may be stored on your device, permits us to improve and customize your.. Salaries posted anonymously by employees to receive a qualified connection, of which 35 in... Of being unconventional but for the sake of being unconventional, not for the sake being... Offering meaningful contribution to team-based like to work at Shape TX AI engine to analyze massive datasets generated our! ) } } 354 employees, of which 35 are in a team or setting!
